Taikang: Phospholipid-complexed iodine tablets obtain the drug re-registration approval notice.

Tiankang Announcement: Recently, the company received the "Woltene" phospholipid iodine complex tablet "Drug Re-registration Approval Notice" issued by the National Medical Products Administration. The generic name of the drug is phospholipid iodine complex tablets, the dosage form is tablets, the specification is 1.5mg/tablet, the drug approval number is National Drug Standard HJ20160151, and the validity period is until March 11, 2031. The company has been acting as the sole general agent for Woltene since 1999, with complete sales pricing rights and control over sales channels and customer resources.